• Revenue for the fourth quarter of 2019 amounted to ISK 4,935 million, a decrease of 9% from the same period in 2018. • The quarter’s EBITDA amounted to ISK 1,409 million, compared to ISK 1,449 million in the fourth quarter of 2018. The EBITDA margin was 28.6% in the fourth quarter of 2019 compared to 26.7% in the same quarter last year.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the NYSE American LLC (the "Exchange") has accepted the Company's plan of compliance (the "Plan") for continued listing on the Exchange.

Yahoo Finance’s Anjalee Khelmani joins Zack Guzman and Akiko Fujita on The Ticker to discuss the biotech outlook as coronavirus cases grow in the U.S.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the "Exchange"), the Company's current listing exchange, stating that it is not in compliance with certain continued listing standards as set forth in the NYSE American Company Guide. Based on the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2019, which was filed with the Securities and Exchange Commission (SEC) on November 4, 2019, the Company is below compliance with Part 10, Section 1003 of the NYSE American Company Guide since it reported stockholders' equity of $4.9 million and net losses in five of its most recent fiscal years as of September 30, 2019.

Q3 2019 Synthetic Biologics Inc Earnings Call

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal ("GI") diseases in areas of high unmet need, today announced that it entered into an agreement with Massachusetts General Hospital ("MGH") granting the Company an option for an exclusive license to intellectual property and technology related to the use of intestinal alkaline phosphatase ("IAP") to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. If executed, the Company plans to use this license in the advancement of an expanded clinical development program for SYN-020, the Company's proprietary recombinant version of bovine IAP currently in pre-clinical development.

At the beginning of the year, the accounting treatment of broadcasting license rights was changed, amounts for 2018 have been restated. EBITDA for the first nine months of 2019 was ISK 4,100 million, a decrease of ISK 153 million from same period in 2018. Profit in the first nine months of the year amounted to ISK 384 million which is an increase of ISK 135 million from same period in 2018.

Q1 2020 Synthetic Biologics Inc Earnings Call

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held on December 2, 2019 at the Company's request to discuss the development of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients who are administered intravenous (IV) beta-lactam antibiotics in response to fever.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Sýn hf.’s Condensed Consolidated Interim Financial Statements for Q1 2020 was approved by the board on May 13th, 2020. • Revenue for the first quarter (Q1) of 2020 amounted to ISK 4,995 million, on par with the same period in 2019. • The quarter’s EBITDA amounted to ISK 1,355 million, compared to ISK 1,260 million in the first quarter of 2019.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the quarter ended March 31, 2020.

Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends to release its operational highlights and financial results for the quarter ended March 31, 2020 on Tuesday, May 5, 2020, and to host a conference call the same day at 4:30 p.m. ET. The dial-in information for the call is as follows:

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2019.

If you're interested in Synthetic Biologics, Inc. (NYSEMKT:SYN), then you might want to consider its beta (a measure...

-- Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) -- ROCKVILLE, Md. , Nov. ...

See attachment: Attachment Landsdowne_SYN_24.12.2019

Q4 2019 Synthetic Biologics Inc Earnings Call

Sýn will host its Annual General Meeting and publish its interim condensed and annual consolidated financial statements according to the below financial calendar: Interim.